Vaccination in CLL

 

Live vaccines, including that for Herpes Zoster Virus (HSV), should be avoided in immunocompromised patients.

In any patient with CLL who has had HSV, prophylactic acyclovir should be continued indefinitely

 

Recommended Vaccination

Patients should ideally be vaccinated at diagnosis and before treatment

• Pneumococcal Conjugate Vaccine (PCV13 or Prenvar 13® ) 
• Haemophilus Influenzae B

and then at least two months later   

• Pneumococcal Polysaccharide Vaccine (PPV23 or Pneumovax® )

 

Response should be assessed with antibody titres (6 months after the second dose)

Response with serotype specific pneumococcal and HiB antibodies will be checked in the haematology department for those patients attending outpatients. Please check these in primary care if they are not being referred for specialist review.

Loss of response may necessitate re-vaccination

• Annual Influenza vaccine should also be given

 

References:

BSH Guideline for treatment of CLL, July 2018 : www.onlinelibrary.wiley.com/doi/full/10.1111/bjh.15460

 

 

 

Contributors:

Dr Richard Noble, Consultant Haematologist, RCHT

Dr Bridgitte Wesson, GP & Kernow RMS Haematology guideline lead

 

Review date: 13/07/2020

Next Review date: 13/07/2021